AIMS: To evaluate the ability of Candida parapsilosis and Candida glabrata to develop phenotypic resistance to a benzophenone enriched fraction obtained from Brazilian red propolis (BZP-BRP) as compared to fluconazole (FLC). To investigate possible synergy between BZP-BRP and FLC and anidulafungin (AND). METHODS AND RESULTS: To analyse the development of resistance, isolates susceptible to these antifungals were cultured in increasing concentrations of FLC and BZP-BRP. The increase in FLC minimum inhibitory concentration for all isolates was evident and the majority developed resistance, whereas none isolated became less susceptible to BZP-BRP. Synergism was investigated by checkerboard method. BZP-BRP demonstrated synergy with FLC and indifference with AND for most isolates. CONCLUSIONS: In conclusion, the synergism observed with FLC suggests that BZP-BRP could be a possible therapeutic strategy for the treatment of infections related to FLC-resistant Candida sp. SIGNIFICANCE AND IMPACT OF THE STUDY: The indiscriminate use of antifungals results in the emergence of drug-resistant strains among previously susceptible populations. BZP-BRP can become an alternative for the treatment of persistent infections caused by Candida sp.
AIMS: To evaluate the ability of Candida parapsilosis and Candida glabrata to develop phenotypic resistance to a benzophenone enriched fraction obtained from Brazilian red propolis (BZP-BRP) as compared to fluconazole (FLC). To investigate possible synergy between BZP-BRP and FLC and anidulafungin (AND). METHODS AND RESULTS: To analyse the development of resistance, isolates susceptible to these antifungals were cultured in increasing concentrations of FLC and BZP-BRP. The increase in FLC minimum inhibitory concentration for all isolates was evident and the majority developed resistance, whereas none isolated became less susceptible to BZP-BRP. Synergism was investigated by checkerboard method. BZP-BRP demonstrated synergy with FLC and indifference with AND for most isolates. CONCLUSIONS: In conclusion, the synergism observed with FLC suggests that BZP-BRP could be a possible therapeutic strategy for the treatment of infections related to FLC-resistant Candida sp. SIGNIFICANCE AND IMPACT OF THE STUDY: The indiscriminate use of antifungals results in the emergence of drug-resistant strains among previously susceptible populations. BZP-BRP can become an alternative for the treatment of persistent infections caused by Candida sp.
Authors: João Guilherme B De Marchi; Denise S Jornada; Fernanda K Silva; Ana L Freitas; Alexandre M Fuentefria; Adriana R Pohlmann; Silvia S Guterres Journal: Int J Nanomedicine Date: 2017-10-25
Authors: Nelly Rivera-Yañez; C Rebeca Rivera-Yañez; Glustein Pozo-Molina; Claudia F Méndez-Catalá; Julia Reyes-Reali; María I Mendoza-Ramos; Adolfo R Méndez-Cruz; Oscar Nieto-Yañez Journal: Biology (Basel) Date: 2021-05-12
Authors: Ticiano Gomes do Nascimento; Priscilla Fonseca da Silva; Lais Farias Azevedo; Louisianny Guerra da Rocha; Isabel Cristina Celerino de Moraes Porto; Túlio Flávio Accioly Lima E Moura; Irinaldo Diniz Basílio-Júnior; Luciano Aparecido Meireles Grillo; Camila Braga Dornelas; Eduardo Jorge da Silva Fonseca; Eduardo de Jesus Oliveira; Alex Tong Zhang; David G Watson Journal: Nanoscale Res Lett Date: 2016-06-17 Impact factor: 4.703